NCT04879628frexalimabfrexalimab1200mgfrexalimab300mgpwRMSrelapsing multiple sclerosisCOVID-19
…ring the 12-week (W) double-blind period of the phase-2 trial ( NCT04879628) in participants with relapsing multiple sclerosis (pwRMS), fre…
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04879628 ×
NCT04879628
This institution is selected. Its supporting articles are shown below.